# Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

> **NCT01110668** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 2 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumor

## Interventions

- **DRUG:** Nilotinib

## Key facts

- **NCT ID:** NCT01110668
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2017-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01110668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01110668, "Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01110668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*